Related Experiment Video
Updated: Feb 14, 2026

A Bioluminescent and Fluorescent Orthotopic Syngeneic Murine Model of Androgen-dependent and Castration-resistant Prostate Cancer
Published on: March 6, 2018
Validating the total illness burden index for prostate cancer (TIBI-CaP) in men with castration-resistant prostate
Scott C Flanders1, Janet Kim1, Samuel Wilson1
1Astellas Pharma, Inc., Northbrook, IL 60062, USA.
Aim:
To validate the total illness burden index for prostate cancer (TIBI-CaP) in castration-resistant prostate cancer (CRPC) patients.
Patients & Methods:
Baseline comorbidity scores collected using the TIBI-CaP were compared with the baseline patient-reported health-related quality of life using the SF-12v2 and FACT-P questionnaires in 302 patients enrolled in the Treatment Registry for Outcomes in CRPC Patients (TRUMPET).
Results:
Baseline TIBI-CaP scores were negatively correlated with all baseline SF-12v2 domain/composite (p < 0.001) and FACT-P subscale/total (p < 0.020) scores. There was a significant decreasing linear trend in SF12v2 and FACT-P scores over the categories based on TIBI-CaP quartiles of comorbidity burden (from 'least' to 'severe').
Conclusion:
The TIBI-CaP is a valid measure of comorbidity burden in patients with CRPC in the real world.
Related Concept Videos
Treatment Resistant Cancers
Data Validation
Key parameters for method validation include:
Data Validation
Nursing assessment guides are generally based on holistic models rather than medical...
Cancer
What is Cancer?
Although people have known about cancer for centuries, it was only in 1761 that Giovanni Morgagni of Padua performed a detailed autopsy of...
Cancer Vaccines
Cancer vaccines come in two categories: preventive (prophylactic) and treatment (active). Preventive vaccines, such as the Human Papillomavirus (HPV) vaccine, protect against viruses that cause certain...

